I work in pharma (not BI) and can add some pipeline context. The MASH treatment landscape is about to get very crowded: Active Phase 3 programs: - Survodutide (BI) — SYNCHRONIZE trials, dual GLP-1/GCGR - Tirzepatide (Lilly) — SYNERGY-NASH, dual GLP-1/GIP - Semaglutide (Novo) — ESSENCE trial results expected soon - Efruxifermin (Akero) — HARMONY Phase 3, FGF21 analog - Pegozafermin (89bio) — ENLIVEN Phase 3, FGF21 analog The FGF21 analogs are interesting because they approach MASH from yet another angle — direct anti-fibrotic and anti-inflammatory effects. Efruxifermin showed ~40% MASH resolution in Phase 2. My prediction: within 3-4 years we'll have 3-4 approved MASH therapies with different mechanisms, and the standard of care for advanced MASH will be combination therapy (similar to how we treat HIV or hepatitis C). Survodutide + FGF21 analog could be a potent combination. For the patient above — your hepatologist should absolutely be aware of these developments. Consider asking about clinical trial enrollment if you're at a center that participates.

Agree with the combination therapy prediction. One thing worth noting about the survodutide data that doesn't get enough attention: the body composition changes. Unlike pure GLP-1 agonists where ~30-40% of weight loss is lean mass, the glucagon component in survodutide appears to preferentially preserve lean mass while targeting visceral and hepatic fat. In the Phase 2b, DEXA substudy showed ~80% of weight loss was fat mass, with visceral fat reduction of ~35%. This is critical for MASH patients because sarcopenia is an independent risk factor for MASH progression and hepatic decompensation. A drug that resolves MASH while preserving muscle mass is basically the holy grail. The liver-specific fat targeting is likely driven by glucagon's direct hepatic effects — it activates hepatic autophagy (lipophagy), increases fatty acid beta-oxidation in hepatocytes, and reduces VLDL secretion. You're essentially telling the liver to burn its own fat stores. For: at F3 you should also be getting surveillance for hepatocellular carcinoma (ultrasound every 6 months). Make sure that's happening regardless of treatment.

Thank you all for the thorough responses. Yes, I'm getting the HCC surveillance — ultrasound every 6 months with AFP levels. Both have been reassuring so far. I'll ask my hepatologist about adding a GLP-1 to the resmetirom. I already have T2D (HbA1c 7.2%) and BMI 38, so there's a clear metabolic indication. I was actually surprised he didn't suggest it initially. One more question — for the survodutide Phase 3, do any of the SYNCHRONIZE trials include patients already on resmetirom? Or would I need to wash out? I'm in the Philadelphia area and my hepatologist is at Penn, so trial enrollment might be possible.

Penn is an excellent center for MASH trials — Dr. Levy's group has been very active. The SYNCHRONIZE program does have exclusion criteria around concomitant MASH therapies, so you'd likely need to wash out resmetirom. That's a conversation to have with the trial investigators directly. However, I'd strongly recommend against discontinuing a therapy that's working (even if modestly) to gamble on randomization into a clinical trial where you might get placebo. If you're randomized to the placebo arm, you've lost months of resmetirom benefit. The better play right now: 1. Continue resmetirom 2. Add semaglutide or tirzepatide for the T2D + obesity (your HbA1c and BMI clearly warrant it) 3. Repeat FibroScan at 12 months to assess combined response 4. Keep an eye on survodutide approval timeline With HbA1c 7.2% and BMI 38, most endocrinologists would start a GLP-1 regardless of the MASH. You get the liver benefit as a bonus. Your 12-month FibroScan will be the key decision point. If you're trending toward F2 on combination therapy, you stay the course. If fibrosis is static or progressing despite dual therapy, that's when we have a harder conversation about trials or transplant evaluation.

One final thought on the survodutide data that's relevant to clinical practice right now: these results validate that aggressive metabolic intervention can reverse established fibrosis. For years, the dogma was that F3-F4 fibrosis was essentially irreversible — you could slow progression but not reverse it. The survodutide data (52% fibrosis improvement) combined with the semaglutide ESSENCE data and the FGF21 analog data are collectively demolishing that dogma. This should change how aggressively we treat early-stage MASH. If we can reverse F3 fibrosis with pharmacotherapy, we should be identifying and treating F1-F2 patients far more aggressively than we currently do. Waiting until patients progress to F3-F4 before initiating therapy is increasingly indefensible. The problem is that most MASH patients in the community are still being told "lose weight and exercise" by PCPs who don't appreciate the fibrosis risk. We need better screening, better risk stratification, and earlier intervention. FIB-4 should be standard in every metabolic syndrome patient.